TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $325,023 | -39.7% | 36,356 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $538,568 | -19.4% | 35,063 | +18.1% | 0.00% | -25.0% |
| Q1 2023 | $667,908 | +9.1% | 29,698 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $612,120 | -14.0% | 29,107 | +0.7% | 0.00% | -20.0% |
| Q3 2022 | $712,000 | +3.0% | 28,913 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $691,000 | -8.5% | 28,505 | -2.7% | 0.01% | +25.0% |
| Q1 2022 | $755,000 | -22.5% | 29,311 | -6.6% | 0.00% | -20.0% |
| Q4 2021 | $974,000 | +25.8% | 31,375 | -1.7% | 0.01% | +25.0% |
| Q3 2021 | $774,000 | +62.3% | 31,907 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $477,000 | -40.7% | 32,665 | +1.3% | 0.00% | -33.3% |
| Q1 2021 | $805,000 | +3.9% | 32,248 | +13.4% | 0.00% | 0.0% |
| Q4 2020 | $775,000 | – | 28,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |